Trevi Therapeutics
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated condi...
Latest News
7 days ago · seekingalpha.com
Trevi Therapeutics, Inc. (TRVI) Q3 2026 Earnings Call TranscriptTrevi Therapeutics, Inc. (TRVI) Q3 2026 Earnings Call Transcript
7 days ago · marketbeat.com
What Trevi Therapeutics (TRVI) Said on Its Q3 Earnings CallTrevi Therapeutics NASDAQ: TRVI said it remains on track to report results from its lead chronic cough trials in 2027 and 2028, while preparing a new study in patients with interstitial lung disease other than idiopathic pulmonary fibrosis.
7 days ago · globenewswire.com
Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdatesInitiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials actively recruiting Positive meeting with the FDA on the non-IPF ILD-related chronic cough program held in October 2026; Phase 2 dose-ranging trial expected to initiate in the first quarter of 2027 Notice of Allowance from the USPTO for patent application covering nalbuphine ER dosing in hepatically impaired patients with non-IPF ILD-related chronic cough, with patent expected to expire in 2041 Cash runway into 2030 funding key clinical milestones Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn.
14 days ago · globenewswire.com
Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026NEW HAVEN, Conn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Monday, November 9, 2026, at 4:30 p.m.
21 days ago · globenewswire.com
Trevi Therapeutics to Participate in Stifel's 2026 Healthcare ConferenceFireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ET Fireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ET
1 month ago · globenewswire.com
Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual MeetingProfessor Philip Molyneaux will present on the patient-reported outcomes from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) Professor Philip Molyneaux will present on the patient-reported outcomes from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF)
2 months ago · seekingalpha.com
Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptTrevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
3 months ago · globenewswire.com
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough
3 months ago · seekingalpha.com
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough PlatformTrevi Therapeutics leverages Haduvio's dual mechanism to target IPF-related chronic cough, with expansion plans into non-IPF ILD and refractory chronic cough. Haduvio's positive Phase II data in both IPF and RCC, ongoing pivotal trials, and robust liquidity underpin TRVI's transition to a specialty pharma platform. TRVI's specialty-first strategy targets concentrated pulmonology networks, enabling efficient market entry and future expansion without large-scale commercial buildout.
3 months ago · marketbeat.com
Trevi Therapeutics Q2 Earnings Call HighlightsTrevi Therapeutics NASDAQ: TRVI said it began two clinical trials during the second quarter and plans to launch a third study in the third quarter as it advances nalbuphine ER, also known as Haduvio, for multiple chronic-cough indications.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove TRVI